In the 64th American Society of Hematology (ASH) Annual Meeting and Exposition 2022, Dr. Laura C. Michaelis from the Medical College of Wisconsin, United States (US), and Dr. Kristen O'Dwyer from the University of Rochester Medical Center, US, presented the current ASH recommendations for less inten

Chronic lymphocytic leukemia (CLL) is a mature B-cell neoplasm characterized by an increased number of circulating clonal B-cells with typical morphology and immunophenotype.¹ Accounting for 25% of all leukemias in adults, CLL is the most common leukemia in the Western world.¹ To address the clinica

The field of immunotherapy has been rapidly evolving and is increasingly utilized in the management of lymphomas.¹ Currently, various immunotherapeutic modalities have been pursued including monoclonal antibodies, bispecific T-cell engagers (BiTEs), checkpoint inhibitors and chimeric antigen recepto

Acute myeloid leukemia (AML) is an aggressive disease that predominantly affects older individuals.¹ While hematopoietic stem-cell transplantation (HSCT) after induction chemotherapy is potentially curative, this option is not feasible for many older AML patients due to advanced age, coexisting cond

Mantle cell lymphoma (MCL) is a B cell malignancy that is typically clinically aggressive with a poor prognosis.¹ When MCL patients progress into relapsed/refractory MCL (RRMCL), the median overall survival (OS) is usually reduced to around 1 year. Currently, three Bruton’s tyrosine kinase inhibitor

Although chronic lymphocytic leukemia (CLL) patients now have a broader selection of treatment options available, therapeutic efficacies of most treatments still largely depend on the patients’ fitness, cytogenetics and previous treatment responses. Some clinically relevant mutations have now been identified to predict

Acute myeloid leukemia (AML) therapy planning usually requires stratification of patients based on their age and performance status. Only young and fit patients would be eligible for intensive chemotherapy, limiting older unfit patients to lower intensity treatment which would usually result in lower long-term survival rate.¹

The risk of death was reduced by 34% among participants receiving the combination of venetoclax and azacitidine (OS HR=0.66, p<0.001); the median overall survival was 14.7 months for venetoclax combination vs. 9.6 months for placebo Among patients on venetoclax and azacitidine, 36.7%

Mantle cell lymphoma (MCL) is an uncommon but aggressive subtype of lymphoid malignancy, generally considered to have a poor prognosis.¹ Although the disease responds well to initial treatment, relapse will inevitably occur,¹